Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

De-differentiation confers multidrug resistance via noncanonical PERK-Nrf2 signaling.

Del Vecchio CA, Feng Y, Sokol ES, Tillman EJ, Sanduja S, Reinhardt F, Gupta PB.

PLoS Biol. 2014 Sep 9;12(9):e1001945. doi: 10.1371/journal.pbio.1001945. eCollection 2014 Sep.

2.

Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stress.

Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, Proia TA, Jin DX, Reinhardt F, Ploegh HL, Wang Q, Gupta PB.

Cancer Discov. 2014 Jun;4(6):702-15. doi: 10.1158/2159-8290.CD-13-0945. Epub 2014 Apr 4.

3.

Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III.

Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, Han SY, Li G, Jensen KC, Vogel H, Xu LW, Skirboll SS, Wong AJ.

Cancer Res. 2014 Feb 15;74(4):1238-49. doi: 10.1158/0008-5472.CAN-13-1407. Epub 2013 Dec 23.

4.

Breakpoint analysis of transcriptional and genomic profiles uncovers novel gene fusions spanning multiple human cancer types.

Giacomini CP, Sun S, Varma S, Shain AH, Giacomini MM, Balagtas J, Sweeney RT, Lai E, Del Vecchio CA, Forster AD, Clarke N, Montgomery KD, Zhu S, Wong AJ, van de Rijn M, West RB, Pollack JR.

PLoS Genet. 2013 Apr;9(4):e1003464. doi: 10.1371/journal.pgen.1003464. Epub 2013 Apr 25.

5.

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms.

Del Vecchio CA, Giacomini CP, Vogel H, Jensen KC, Florio T, Merlo A, Pollack JR, Wong AJ.

Oncogene. 2013 May 23;32(21):2670-81. doi: 10.1038/onc.2012.280. Epub 2012 Jul 16.

PMID:
22797070
6.

Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma.

Del Vecchio CA, Jensen KC, Nitta RT, Shain AH, Giacomini CP, Wong AJ.

Cancer Res. 2012 May 15;72(10):2657-71. doi: 10.1158/0008-5472.CAN-11-2656. Epub 2012 Mar 14.

7.

Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.

Modjtahedi H, Khelwatty SA, Kirk RS, Seddon AM, Essapen S, Del Vecchio CA, Wong AJ, Eccles S.

Br J Cancer. 2012 Feb 28;106(5):883-8. doi: 10.1038/bjc.2012.27. Epub 2012 Feb 7.

8.

Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.

Del Vecchio CA, Li G, Wong AJ.

Expert Rev Vaccines. 2012 Feb;11(2):133-44. doi: 10.1586/erv.11.177. Review.

PMID:
22309662
9.
10.

The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis.

Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ.

Oncogene. 2011 Jan 13;30(2):234-44. doi: 10.1038/onc.2010.414. Epub 2010 Sep 27.

Supplemental Content

Loading ...
Support Center